AstraZeneca has supply and manufacturing facilities in Delaware and Massachusetts.
Newark, Delaware
AstraZeneca's U.S. supply and manufacturing division, located in Newark, Delaware, opened in 1971. One of the first products produced at this facility was the popular antacid Mylanta. This facility houses some of the most advanced pharmaceutical production and technical support in the nation.
Products formulated and packaged at this location include cardiovascular, oncology, infection, respiratory, gastrointestinal, anesthetics, and neuroscience treatments. The supply facility also serves as a major distribution and shipping center.
The most well known products produced here are SERQOUEL®, ARIMIDEX®, and MERREM®.
The commitment to modernization and expansion at this facility has been ongoing. After nearly three decades, this 145-acre site has over 640,000) square feet of facilities. The Newark Supply Site is a designated Foreign Trade Zone.
The Newark Supply Site was awarded the ENERGY STAR for plants in March 2009. This award resulted from site improvements implemented as part of a five-year plan to reduce energy usage and CO2 emissions, an AstraZeneca global goal for 2010.
AstraZeneca Pharmaceuticals LP
587 Old Baltimore Pike
Newark, DE 19702
Westborough, Massachusetts
Located in picturesque central Massachusetts, the Westborough site was commissioned in 1979 and completed in 1983, after phasing out a supply and manufacturing facility in Worcester, Massachusetts, built in 1948. The site has evolved from primarily supplying parenteral (sterile injectable) products to becoming a multipurpose facility capable of supply and packaging of sterile injectables, topicals, and respiratory products. Over the years, many new technologies have been introduced to enhance production efficiencies and product quality.
The most well known products produced here are PULMICORT RESPULES® (budesonide inhalation suspension) and RHINOCORT AQUA® (budesonide).
The Westborough Supply Site was awarded the ENERGY STAR for plants in March 2009. This award resulted from site improvements implemented as part of a five-year plan to reduce energy usage and CO2 emissions, an AstraZeneca global goal for 2010.
AstraZeneca Pharmaceuticals LP
50 Otis Street
Westborough, MA 01581-4500
